Literature DB >> 28097342

Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.

John P Middleton1, Myles Wolf1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28097342      PMCID： PMC5507610          DOI： 10.1001/jama.2016.18631

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  17 in total

1.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

Review 2.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

3.  Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

Authors:  Vasily Belozeroff; Glenn M Chertow; Christopher N Graham; Bastian Dehmel; Patrick S Parfrey; Andrew H Briggs
Journal:  Value Health       Date:  2015-10-09       Impact factor: 5.725

4.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

Authors:  Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

5.  Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.

Authors:  Geoffrey A Block; David A Bushinsky; Sunfa Cheng; John Cunningham; Bastian Dehmel; Tilman B Drueke; Markus Ketteler; Reshma Kewalramani; Kevin J Martin; Sharon M Moe; Uptal D Patel; Justin Silver; Yan Sun; Hao Wang; Glenn M Chertow
Journal:  JAMA       Date:  2017-01-10       Impact factor: 56.272

6.  Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Authors:  Sharon M Moe; Glenn M Chertow; Patrick S Parfrey; Yumi Kubo; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Charles A Herzog; Gerard M London; Kenneth W Mahaffey; David C Wheeler; Maria Stolina; Bastian Dehmel; William G Goodman; Jürgen Floege
Journal:  Circulation       Date:  2015-06-09       Impact factor: 29.690

7.  Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.

Authors:  M Jadoul; J M Albert; T Akiba; T Akizawa; L Arab; J L Bragg-Gresham; N Mason; K-G Prutz; E W Young; R L Pisoni
Journal:  Kidney Int       Date:  2006-08-23       Impact factor: 10.612

8.  Long interdialytic interval and mortality among patients receiving hemodialysis.

Authors:  Robert N Foley; David T Gilbertson; Thomas Murray; Allan J Collins
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

9.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

Authors:  Geoffrey A Block; Kevin J Martin; Angel L M de Francisco; Stewart A Turner; Morrell M Avram; Michael G Suranyi; Gavril Hercz; John Cunningham; Ali K Abu-Alfa; Piergiorgio Messa; Daniel W Coyne; Francesco Locatelli; Raphael M Cohen; Pieter Evenepoel; Sharon M Moe; Albert Fournier; Johann Braun; Laura C McCary; Valter J Zani; Kurt A Olson; Tilman B Drüeke; William G Goodman
Journal:  N Engl J Med       Date:  2004-04-08       Impact factor: 91.245

10.  Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.

Authors:  Patrick H Pun; Safa Abdalla; Geoffrey A Block; Glenn M Chertow; Ricardo Correa-Rotter; Bastian Dehmel; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Gerard M London; Kenneth W Mahaffey; Sharon M Moe; Patrick S Parfrey; David C Wheeler; John P Middleton
Journal:  Hemodial Int       Date:  2015-11-13       Impact factor: 1.812
View more
  2 in total

Review 1.  Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.

Authors:  Mario Cozzolino; Andrea Galassi; Ferruccio Conte; Michela Mangano; Luca Di Lullo; Antonio Bellasi
Journal:  Ther Clin Risk Manag       Date:  2017-06-01       Impact factor: 2.423

2.  New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology.

Authors:  Antonio Bellasi; Mario Cozzolino; Fabio Malberti; Giovanni Cancarini; Ciro Esposito; Carlo Maria Guastoni; Patrizia Ondei; Giuseppe Pontoriero; Ugo Teatini; Giuseppe Vezzoli; Marzia Pasquali; Piergiorgio Messa; Francesco Locatelli
Journal:  J Nephrol       Date:  2019-12-18       Impact factor: 3.902
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.